Bharat Biotech's homegrown COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, the Indian company said on Wednesday.
The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian government's medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6%, the company said.
India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
India's vaccination drive, currently underway, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca.
Earlier this week, Indian Prime Minister Narendra Modi was inoculated with the first dose of COVAXIN.
Israeli troops and tanks pushed on Saturday into parts of a congested northern Gaza Strip district that they had previously skirted in the more than seven-month-old war, killing and wounding dozens of Palestinians, medics and residents said.
Slovak Prime Minister Robert Fico is no longer in immediate danger but still in a serious condition, his deputy said on Sunday, four days after an assassination attempt that sent shockwaves through Europe.
At least 47 people have died after continued heavy rain and flooding in northern Afghanistan, an official said on Sunday, a day after a similar number were killed in a central province.
Russian airstrikes killed at least ten people and injured many others in a recreation area just outside Ukraine's northeastern city of Kharkiv on Sunday, local officials said.